Analyst Update: Micron Technology, Inc., Baidu Inc (ADR), and West Pharmaceutical Services Inc.

Analysts are weighing in on semiconductor stock Micron Technology, Inc. (NASDAQ:MU), internet issue Baidu Inc (ADR) (NASDAQ:BIDU), and healthcare concern West Pharmaceutical Services Inc. (NYSE:WST). Here's a quick roundup of today's brokerage notes on MU, BIDU, and WST.

• MU is up 3.3% at $17.47, after Nomura raised its price target on the stock to $23 from $20, a level the shares haven't touched in well over a year. While the stock has been marching higher in recent months -- boasting a year-to-date lead of 23% -- Micron Technology, Inc.'s rally has encountered some trouble in the $17-$17.50 area. Meanwhile, options traders continue to bet on more gains for the shares. At the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), MU's 10-day call/put volume ratio of 4.05 not only shows long calls have outpaced puts 4-to-1 over the past two weeks, but it ranks higher than 77% of comparable readings taken in the past year.

• Deutsche Bank increased its price target on BIDU to $219 from $182 -- in annual-high territory -- sending the shares 4.7% higher to $195.22. The stock has been rallying since late July, bringing it face to face with the $194-$195 region, an area that shut down multiple breakout attempts back in April. Meanwhile, Baidu Inc's Schaeffer's put/call open interest ratio (SOIR) of 1.07 sits in the 85th percentile of its 12-month range, indicating near-term speculators are unusually put-heavy toward the stock. Short interest on BIDU has been edging up, too, climbing 10.5% during the most recent two-week reporting period -- though less than 2% of the equity's available float is wrapped up in these bearish bets.

• WST has dropped 8.6% to $74.30, after Wells Fargo downgraded the stock to "market perform" from "outperform." The gap lower has West Pharmaceutical Services Inc. on track to close below its 80-day moving average for the first time since February, but the shares are still sitting on a healthy 23% year-over-year lead. This bearish brokerage note runs counter to the withstanding bias seen among the brokerage bunch. Heading into today's trading, three-quarters of analysts rated the stock a "strong buy," without a single "sell" on the books.